A “Precedent-Setting” OTC Switch – And A Case Study In Disregarding FDA’s Advice
Executive Summary
FDA urged the Differin OTC switch advisory committee to consider the application as “precedent setting” given the theoretical risk of teratogenicity – but one committee member was more worried about the bad precedent of approving an application for a sponsor that didn’t do a label comprehension study the way FDA requested.